Overview
Pediococcus acidilactici is a Gram-positive, homofermentative, coccoid lactic acid bacterium that has attracted growing interest as a probiotic, particularly for immune stimulation and metabolic health applications. While uncommon as a permanent gut resident, the species is widely distributed in fermented plant foods and has a long history of safe use in food preservation due to its production of pediocin, a potent bacteriocin with activity against foodborne pathogens including Listeria monocytogenes.
Recent research has expanded the known health applications of P. acidilactici beyond food safety to include IgA-mediated intestinal immune activation, anti-obesity effects, and non-alcoholic fatty liver disease (NAFLD) prevention, positioning it as an emerging probiotic species with diverse therapeutic potential.
Classification
P. acidilactici belongs to the family Lactobacillaceae within the order Lactobacillales. It is a Gram-positive, non-motile, non-spore-forming coccus that typically occurs in pairs or tetrads. The species is homofermentative, producing primarily DL-lactic acid from glucose. The type strain is ATCC 8042. P. acidilactici is thermotolerant relative to other pediococci, capable of growth at temperatures up to 50 degrees Celsius, which distinguishes it from the closely related P. pentosaceus.
Key Characteristics
A defining feature of P. acidilactici is its production of pediocin, a class IIa bacteriocin with strong antimicrobial activity against Gram-positive pathogens. Pediocin PA-1 is one of the most studied bacteriocins and has demonstrated effective inhibition of Listeria monocytogenes, making P. acidilactici strains valuable for food biopreservation. Strain SN-8 is specifically recognized as a potent pediocin producer.
Beyond its antimicrobial properties, P. acidilactici has demonstrated the ability to stimulate secretory IgA production in the intestine, a key component of mucosal immunity. Research also indicates that certain strains may significantly influence lipid metabolism, with strain FZU106 shown to regulate serum and liver lipid levels in high-fat diet models.
Health Significance
The health significance of P. acidilactici encompasses immune, metabolic, and antimicrobial domains. Clinical research suggests that the species may promote IgA production and improve intestinal flora composition, supporting mucosal immune defense. Strain CNCM I-4622 has received European EFSA approval and demonstrates documented intestinal morphology improvements.
Emerging metabolic health research is particularly notable. Studies indicate that strain PA53 may demonstrate superior efficacy compared to curcumin in preventing NAFLD onset, with significant reductions in body weight gain, hepatic lipid accumulation, and systemic inflammation through gut-liver axis modulation. Similarly, strain FZU106 has shown protective effects against high-fat diet-induced hyperlipidemia. While much of this metabolic research remains in preclinical stages, these findings suggest P. acidilactici may have meaningful applications in metabolic health management.